Publication details
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia
| Authors | |
|---|---|
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Hematological Oncology |
| MU Faculty or unit | |
| Citation | |
| Web | Full Text |
| Doi | http://dx.doi.org/10.1002/hon.2091 |
| Field | Oncology and hematology |
| Keywords | CML; imatinib; plasma concentration; cell-asscociated concentration |
| Attached files | |
| Description | This multicentre study focused on monitoring imatinib mesylate(IMA)trough plasma(Ctrough) and intracellular (IMA Cintrac) concentrations in 228 chronic myelogenous leukaemia patients. We found a correlation between IMA Ctrough and alpha 1-acid glycoprotein plasma concentrations. All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or bodymass index) impact onmeasured IMA Ctrough. The IMA Ctrough decreased during the first 6months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p=0.273) and the 12th month (p = 0.193) of therapy. Our data obtained from real life clinical practice did not find a benefit of routine and regular IMA Ctrough nor IMA Cintrac therapeutic drug monitoring in CML patients or for subsequent adjustments of the IMA dose based on these results. Moreover, actual alpha 1-acid glycoprotein plasma concentration should be used for proper interpretation of IMA Ctrough results. |
| Related projects: |